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181Carotid Artery Stenting for Recurrent Carotid Artery Restenosis After
Previous Ipsilateral Carotid Artery Endarterectomy or Stenting
A Report From the National Cardiovascular Data RegistryObjectives The purpose of this study was to evaluate and compare outcomes of patients undergoing carotid artery stenting (CAS)
for ipsilateral restenosis, after either previous CAS or carotid artery endarterectomy (CEA) (CAS-R group), with those of patients who
had CAS performed for de novo carotid atherosclerotic stenosis (CAS-DN group).
Background Therapeutic revascularization strategies to reduce stroke include CAS and CEA. Limited data exist concerning the
outcomes of CAS in the setting of previous ipsilateral carotid revascularization.
Methods Patients enrolled in the CARE (Carotid Artery Revascularization and Endarterectomy) registry who underwent CAS were
identiﬁed and separated into 2 groups: those undergoing CAS after previous ipsilateral CEA or CAS (CAS-R group, n ¼ 1,996) and
those who had CAS performed for de novo atherosclerotic carotid stenosis (CAS-DN group, n ¼ 10,122). We analyzed the clinical
and procedural factors associated with CAS-R and CAS-DN between January 1, 2005, and October 8, 2012. Propensity score
matching using 19 clinical and 9 procedural characteristics was used, yielding 1,756 patients in each CAS cohort.
Results The primary endpoint composite of in-hospital death or stroke or myocardial infarction (MI) occurred less often in the
CAS-R compared with CAS-DN patients (1.9% vs. 3.2%; p ¼ 0.019). In-hospital adverse cerebrovascular events (stroke or transient
ischemic attack) occurred less frequently in the CAS-R cohort (2.2% vs. 3.6%; p < 0.001). However, there was no signiﬁcant
difference in the composite of death, stroke, or MI at 30 days between both groups.
Conclusions Patients who underwent CAS for restenosis after previous ipsilateral revascularization had lower periprocedural
adverse event rates and comparable 30-day adverse event rates compared with CAS for de novo carotid artery stenosis.
(J Am Coll Cardiol Intv 2014;7:180–6) ª 2014 by the American College of Cardiology FoundationCarotid artery revascularization strategies include carotid
artery endarterectomy (CEA) and carotid artery stenting
(CAS) (1). However, the optimal management strategy of
obstructive atherosclerotic carotid artery disease after previ-
ous ipsilateral revascularization, with either CEA or CAS,
remains unclear. Severe carotid artery restenosis or occlusion
after previous surgical or endovascular treatment is associated
with an increased risk of adverse cerebrovascular events (2).
Revascularization may be indicated for CAS in-stent reste-
nosis, failure of CEA, or progression of stenosis adjacent to
the previous operative or endovascular interventional site.
The purpose of this study, using CARE (Carotid Artery
Revascularization and Endarterectomy) registry data, was
to evaluate and compare outcomes of patients undergoing
CAS for ipsilateral restenosis, either after previous CAS or
CEA (CAS-R group), with those of patients who had CAS
performed for de novo carotid atherosclerotic stenosis (CAS-
DN group). We identiﬁed clinical and procedural charac-
teristics of patients requiring CAS after previous ipsilateral
carotid revascularization. Within these 2 groups (CAS-RConference Management, Harvard Clinical Research Institute, Contego, Micell,
Medicines Company, and Becker Ventures; has equity in Lumen Biomedical, Medical
Stimulation Corp., Angioguard (Cordis), and Micell; and has served on the board of
directors of VIVA Physicians (501C3). Dr. Garasic has received consulting/advisoryand CAS-DN), we also examined outcomes stratiﬁed by the
presence of symptomatic carotid artery disease.
Methods
TheCARE registry is an initiative of the AmericanCollege of
Cardiology Foundation, Society for Cardiovascular Angiog-
raphy and Interventions, Society of Interventional Radiology,
American Academy of Neurology, American Association of
Neurological Surgeons/Congress of Neurological Surgeons,
Society for Vascular Medicine, and Society of Vascular and
Interventional Neurology.
Details pertaining to the CARE registry have been
described in depth elsewhere (3). Brieﬂy, this registry was
established to document and review clinical outcomes for
patients undergoing carotid artery revascularization. Data
relating to clinical characteristics, procedural appropriate-
ness, and 30-day outcomes are included. Independent
neurological assessment using the National Institutes of
Health Stroke Scale performed immediately before and afterboard fees from and has an equity interest in Access Closure, Inc. All other authors have
reported that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received July 3, 2013; revised manuscript received November 1,
2013, accepted November 7, 2013.
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182a procedure, in addition to at a 30-day time point, is a key
component. A Web-based data collection tool is used, and
the National Cardiovascular Data Registry is responsible for
ensuring data consistency and accuracy. Variables and data
deﬁnitions used for the purpose of the CARE registry were
detailed recently (4) and are available at http://www.ncdr.
com/WebNCDR/care/home/datacollection.
All study deﬁnitions were derived from the CARE registry
data dictionary elements and deﬁnitions version 1.08.
In-hospital adverse events refer to new events occurring during
or after CAS but before hospital discharge. Transient ischemic
attack (TIA) was deﬁned as a focal neurological abnormality of
sudden onset, lasting <24 h, and presumed to be ischemic in
origin. Ischemic stroke was deﬁned as the occurrence of a focal
neurological abnormality resulting in ischemic symptoms
persisting>24 h and leading to impaired functional outcomes.
In-hospital mortality was deﬁned as death occurring during the
procedure or before hospital discharge. Acute myocardial in-Abbreviations
and Acronyms
CAS = carotid artery stenting
CEA = carotid
endarterectomy
CAS-R = carotid artery
stenting for ipsilateral
restenosis after previous
carotid artery
revascularization
CAS-DN = carotid artery
stenting performed for de
novo carotid atherosclerotic
stenosis
MI = myocardial infarction
TIA = transient ischemic
attackfarction (MI) was deﬁned as an
increase and decrease in cardiac
biomarkers with at least 1 of the
values above normal for the hos-
pital laboratory (>99th percen-
tile of the upper reference range),
together with evidence of myo-
cardial ischemia deﬁned as at
least 1 of the following: ischemic
symptoms, electrocardiographic
changes indicative of new ische-
mia (new ST–T-wave changes or
new left bundle branch block),
development of pathological Q
waves on the electrocardiogram,
and imaging evidence of new loss
of viable myocardium or new
regional wall motion abnormality.Patients. CARE registry records of patients who underwent
CAS from January 1, 2005, through October 8, 2012, were
reviewed. The records of all CAS patients enrolled in the
registry were included for analysis with the exception of those
having an acute evolving stroke, a spontaneous intracranial
hemorrhage within the previous 180 days, severe dementia,
CAS performed with the patient under general anesthesia, or
nonatherosclerotic carotid artery disease. Those undergoing
CAS for ipsilateral restenosis after previous carotid artery
revascularization (CAS-R) and those who had CAS per-
formed for de novo atherosclerotic carotid artery stenosis
(CAS-DN) were identiﬁed.
Outcomes. The primary outcome of this study was a com-
posite of in-hospital death/MI/stroke and its individual
components. Secondary outcomes included 30-day com-
posite of death/MI/stroke and its individual components.
Statistical analysis. Initially, we compared patient and
procedural characteristics as well as in-hospital outcomesbetween patients with previous ipsilateral procedures and
those without using t tests or chi-square tests. To determine
whether differences in outcomes between the previous
ipsilateral procedure groups could be accounted for by
assessed patient and procedural characteristics, we devel-
oped a saturated propensity score model predicting previous
ipsilateral procedure conditioned on 33 covariates using
logistic regression. Outcomes were compared between the
CAS-DN and -R groups by conditional logistic regression
to account for the propensity match. The propensity score
model had a c-index of 0.715. We used the propensity score
to create a balanced cohort by using a 1-to-1 match with a
caliper width of 0.2 times the SD of the logit (5). To examine
the ability of the propensity score to balance the socio-
demographic and clinical characteristics of patients with and
without a previous ipsilateral procedure, we compared the
overall standardized differences in clinical covariates before
and after matching. The standardized difference is 100
times the absolute difference in sample means divided by an
estimate of the pooled SD of the variable and represents the
difference in means between the 2 groups in units of SD.
This represents the preferred metric in assessing the pro-
pensity score (6). The results of the propensity score to
balance characteristics is shown in Tables 1 and 2; all vari-
ables included in the match had an SD <10% indicating
quality balance (7). Statistical analyses were performed by
the Saint Luke’s Mid America Heart Institute Department
of Biostatistics using SAS version 9.2 (SAS Institute, Cary,
North Carolina).
Results
A total of 12,361 patients who underwent CAS from
January 1, 2005, through October 8, 2012, were included
in this analysis. Patients undergoing ipsilateral CAS for
restenosis of previous carotid artery revascularization
(CAS-R, n ¼ 1,996, 16.1%) were identiﬁed. Of these, 262
had undergone ipsilateral previous CAS, whereas 1,734
had undergone CAS for post-CEA restenosis. After
matching, there was a balanced cohort of 2,512 (1,756 in
each group); 30-day follow-up data were available for 2,736
patients (77.90%): CAS-R: n ¼ 1,366 (77.79%) and CAS-
DN: n ¼1,370 (78.02%).
The clinical and procedural characteristics for the unad-
justed and propensity score-matched patients are detailed
in Tables 1 and 2. As noted in Table 1, there were many
signiﬁcant differences between the unadjusted CAS-R
and -DN groups. A greater percentage of females comprised
the CAS-R group (45.4% vs. 36.9%; p < 0.001). A history
of current or previous tobacco use, hypertension, dyslipide-
mia, and peripheral arterial disease were more prevalent in
those needing repeat revascularization. Rates of heart failure
and atrial ﬁbrillation or ﬂutter were less common than in
the CAS-DN patients. The proportion of patients with
Table 1. Demographic and Clinical Variables by Treatment Group Among Unadjusted and Propensity-Matched Cohort
Unadjusted Cohort Propensity-Matched Cohort
Characteristic
Previous
Revascularization
(n ¼ 1,996)
No Previous
Revascularization
(n ¼ 10,122)
Standardized
Difference
Previous
Revascularization
(n ¼ 1,756)
No Previous
Revascularization
(n ¼ 1,756)
Standardized
Difference
Age, yrs 70.3  9.3 70.7  10.7 4.6578 70.3  9.3 70.1  10.7 1.5453
Male 54.6 63.1 16.9670 54.3 56.3 4.0083
Caucasian 95.1 91.5 14.6120 95.0 95.7 3.4982
Pre-procedure creatinine, mg/dl 1.19  0.65 1.21  0.77 2.3959 1.18  0.63 1.18  0.77 0.1073
Smoker 77.8 73.7 10.4476 77.9 77.9 0.2739
Hypertension 93.7 90.3 12.7667 93.4 94.4 4.2850
Dyslipidemia 89.5 87.0 7.5576 89.4 90.0 2.0572
Peripheral arterial disease 52.8 40.8 23.6001 52.1 52.9 1.5960
Diabetes 35.8 38.1 4.8432 35.5 35.7 0.3567
Ischemic heart disease 51.0 56.9 11.8289 50.7 51.8 2.1642
History of heart failure 14.1 18.6 12.1707 13.9 14.4 1.3078
History of atrial ﬁbrillation or ﬂutter 10.7 13.1 7.2163 10.7 10.6 0.3691
Dementia 2.2 3.1 5.8462 2.3 1.94 2.3786
Target lesion symptomatic within past 6 months 36.3 41.2 10.0650 36.7 38.1 2.9420
Previous TIA 32.7 31.7 2.2340 32.7 34.1 2.8967
Previous ischemic stroke 16.1 14.6 4.1823 15.7 15.8 0.1563
Previous hemorrhagic stroke 0.7 0.6 0.5723 0.7 0.7 0.6772
Pre-procedure NIHSS score 0.8  2.2 0.75  2.2 0.5750 0.8  2.2 0.7  2.1 0.2370
Pre-procedure Modiﬁed Rankin Scale score 0.5  0.9 0.5  0.9 0.4830 0.5  0.9 0.5  0.9 0.7400
Values are mean  SD or %.
NIHSS ¼ National Institutes of Health Stroke Scale; TIA ¼ transient ischemic attack.
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183symptomatic target lesions in the 6-month period before
CAS was higher in CAS-DN group (41.2% vs. 36.3%; p <
0.001). The pre-procedure neurological status as assessed
by the National Institutes of Health Stroke Scale was
comparable between both patient groups. Likewise, previous
TIA (31.7% vs. 32.7%; p ¼ 0.352) and ischemic stroke ratesTable 2. Procedure-Related Variables by Treatment Group Among Unadjusted an
Unadjusted Cohort
Angiographic Characteristics
Previous
Revascularization
(n ¼ 1,996)
No Previous
Revascularization
(n ¼ 10,122)
Aortic arch type 1 56.4 51.3
Bovine aortic arch 12.9 13.7
Visible thrombus present 3.0 3.2
Calciﬁcation present 44.4 67.6
Ulceration 19.1 30.7
Lesion length, mm 18.6  11.7 19.9  9.9
Minimal lumen diameter, mm 1.9  2.1 1.8  2.0
Pre-procedure stenosis 84.7  10.4 84.3  11
Fluoroscopy time, min 19.0  15.0 17.5  13.1
Embolic protective device use 97.4 97.1
Final minimal luminal diameter, mm 5.5  1.7 5.3  1.6
Final stenosis 7.2  10.9 9.2  12.0
High-volume operator, >10/quarter 15.9 25.2
Values are % or mean  SD.(14.6% vs. 16.1%; p ¼ 0.81) were similar for the CAS-DN
and -R patients, respectively.
Procedural characteristics. Patients in the CAS-DN group
were more likely to have their procedure performed by a
high-volume operator, deﬁned as >10 CAS procedures per
quarter (CAS-DN: 25.2% vs. CAS-R: 15.9%; p < 0.001).d Propensity-Matched Cohort
Propensity-Matched Cohort
Standardized
Difference
Previous
Revascularization
(n ¼ 1,756)
No Previous
Revascularization
(n ¼ 1,756) p Value
8.8359 56.4 56.4 0.5154
2.1354 12.9 12.4 1.5107
1.0416 3.0 2.5 2.7935
46.6414 53.4 54.3 2.5432
26.5903 19.4 19.7 0.7176
11.6133 18.6  11.7 18.9  9.3 2.5439
7.2976 1.9  2.2 1.9  2.0 1.3750
4.1352 84.8  10.5 83.6  11.4 11.0897
10.5416 18.8  14.6 17.1  14.6 11.9645
1.6459 98.0 97.6 2.6878
10.6906 5.5  1.7 5.3  1.7 11.0550
17.3930 7.3  10.8 9.2  11.3 17.8287
23.1966 15.6 16.2 1.5574
Table 3. In-Hospital and 30-Day Outcomes After Propensity-Score
Matching for Patients Undergoing Carotid Artery Stenting
Previous
Revascularization
(n ¼ 1,756)
No Previous
Revascularization
(n ¼ 1,756) p Value
In-hospital outcomes
All patients, %
Death 0.3 0.7 0.012
New stroke or TIA 2.2 3.6 <0.001
Stroke 1.4 2.4 0.036
TIA 0.8 1.3 0.180
MI 0.3 0.5 0.592
Death, stroke, or MI 1.9 3.2 0.019
Symptomatic patients, % n ¼ 644 n ¼ 669
Death 0.5 1.35 0.94
New stroke or TIA 3.1 5.4 0.041
Stroke 1.7 3.7 0.024
TIA 1.4 1.6 0.71
MI 0.31 0.6 0.44
Death, stroke, or MI 2.3 4.8 0.017
Asymptomatic patients, % n ¼ 1,112 n ¼ 1,087
Death 0.2 0.3 0.64
New stroke or TIA 1.7 2.6 0.16
Stroke 1.3 1.6 0.54
TIA 0.5 1.0 0.12
MI 0.4 0.4 0.97
Death, stroke, or MI 1.7 2.2 0.40
30-day outcomes
All patients, % n ¼ 1,366 n ¼ 1,370
Death 0.66 0.95 0.40
Stroke 3.22 4.53 0.077
MI 0.88 1.24 0.355
Death, stroke, or MI 4.61 6.28 0.055
Symptomatic patient, % n ¼ 452 n ¼ 494
Death 0.66 2.02 0.073
Stroke 4.42 7.29 0.062
MI 1.33 1.42 0.906
Death, stroke, or MI 6.19 9.51 0.059
Asymptomatic patient, % n ¼ 914 n ¼ 876
Death 0.66 0.34 0.35
Stroke 2.63 2.97 0.66
MI 0.66 1.14 0.28
Death, stroke, or MI 3.83 4.45 0.51
Values are %.
MI ¼ myocardial infarction; TIA ¼ transient ischemic attack.
Hynes et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 2 , 2 0 1 4
Carotid Stenting After Previous Revascularization F E B R U A R Y 2 0 1 4 : 1 8 0 – 6
184Mean ﬂuoroscopy time was longer in the CAS-R group
(19.0  15.0 min vs. 17.5  13.1 min; p < 0.001), despite a
greater number of patients having a more favorable type
1 aortic arch compared with the CAS-DN group (56.4%
vs. 51.3%; p < 0.001). Carotid artery plaque morphology
tended to be longer and more complex in the CAS-DN
group, with a higher likelihood of ulceration (30.7% vs.
19.1%; p < 0.001) and calciﬁcation (67.6% vs. 44.4%;
p < 0.001). The high rate of embolic protective device
deployment during CAS (CAS-R: 97.4% vs. CAS-DN:97.1%; p ¼ 0.492) was comparable in both patient subsets.
Final minimal luminal diameter was minimally greater
in the CAS-R group (5.5  1.7 mm vs. 5.3  1.6 mm;
p < 0.001).
The discrimination of the propensity score was adequate,
and propensity matching succeeded in matching 1,756 of
the 1,996 CAS-R patients with those undergoing CAS for
de novo carotid stenosis. As detailed in Tables 1 and 2, the 2
groups were well matched with regard to risk factor preva-
lence and procedural characteristics, and the standardized
difference was below the recommended maximal value of
10% for every factor.
In-hospital outcomes. Clinical outcomes in the propensity-
matched groups are given in Table 3. The CAS-R group
experienced a lower rate of composite of in-hospital death,
stroke, or MI compared with the CAS-DN group (1.9% vs.
3.2%; p ¼ 0.019). A lower in-hospital mortality rate was
observed for the CAS-R group (0.3% vs. 0.7%; p ¼ 0.012).
The adverse neurological event (new stroke or TIA) rate was
signiﬁcantly lower in the repeat revascularization cohort
(CAS-R: 2.2% vs. CAS-DN: 3.6%; p < 0.001). No sig-
niﬁcant differences in MI or TIA rates were recorded.
For asymptomatic patients, there was no signiﬁcant dif-
ference in the primary outcome composite (in-hospital death,
stroke, or MI) (CAS-R: 1.7% vs. CAS-DN: 2.2%; p ¼ 0.40).
However, among symptomatic patients, the primary outcome
composite was lower in those having repeat revascularization
(2.3% vs. 4.8%; p ¼ 0.017). Procedure-related stroke or TIA
rates were also lower among symptomatic patients in the
CAS-R group (3.1% vs. 5.4%; p ¼ 0.041). Within the CAS-
R group, no signiﬁcant difference was found with regard to
the composite of in-hospital death, stroke, or MI between
patients who underwent repeat CAS (n ¼ 262) and those
who had CAS after a previous CEA (n ¼ 1,734) (0.76% vs.
2.19%; p ¼ 0.124) (Online Table 1). However, the numbers
in the previous CAS group were low, rendering this an un-
derpowered comparison.
Secondary outcomes. The 30-day composite rate of death,
stroke, or MI was not signiﬁcantly different (CAS-R: 4.61%
vs. CAS-DN: 6.28%; p ¼ 0.055) (Table 3). Likewise, the
30-day stroke rate was not signiﬁcantly lower in those pa-
tients undergoing CAS after previous revascularization
(3.22% vs. 4.53%; p ¼ 0.077). In addition, there were no
signiﬁcant differences in outcomes between the CAS-R
and -DN groups at 30 days stratiﬁed by symptom status.
Discussion
Severe restenosis (70%) within the 12-month period after
previous carotid artery revascularization has been shown to
be associated with signiﬁcantly higher nonperioperative
stroke or TIA rates (2). Secondary analysis of CREST
(Carotid Revascularization Endarterectomy Versus Stenting
Trial) reported a higher risk of ipsilateral stroke in patients
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185in whom restenosis developed within 2 years after CAS or
CEA (hazard ratio: 4.37, 95% conﬁdence interval: 1.91 to
10.03; p ¼ 0.0005, adjusted for age, sex, and symptomatic
status) (8). Restenosis after CEA has been reported to occur
in 2.8% to 36% of cases, depending on the deﬁnition, im-
aging modality, and length of follow-up used (8–13).
However, rates of symptomatic restenosis appear to be much
lower (2% to 4%) (14,15). Considerable variation in the
documented rates of restenosis after CAS also exists, from
<3% to >16% (2,8,16–20). Medium-term follow-up of the
CREST trial found that severe carotid artery restenosis
(70% or occlusion) was infrequent and CAS was as durable
as CEA, with restenosis rates of 6.0% and 6.3%, respec-
tively, at 2 years (8).
This study adds to the information concerning CAS after
restenosis, and to our knowledge, the cohort described here
represents the largest amount of reported data in this clinical
setting. After propensity-matched analysis, we found that
CAS-R patients, had a lower rate of the composite of
in-hospital death, stroke, or MI compared with CAS-DN
patients. Although females comprised only 38.54% of the
CAS-DN group, this proportion increased to 46.27% of
those requiring repeat revascularization (p < 0.001). Previ-
ous studies have shown that female sex is associated with a
signiﬁcant risk of restenosis after CEA (21,22). This may be
due to smaller arterial dimensions, which also have been
implicated in restenosis after endovascular stent placement
in other arterial networks (23,24).
Although restenosis after previous CEA or CAS is
generally considered a benign entity due to a perceived lower
thromboembolic risk, 36% of the lesions in the CAS-R
group were symptomatic within 6 months of repeat revas-
cularization. However, this may reﬂect a selection bias in
that symptomatic de novo carotid artery disease patients are
referred more frequently for CEA. A greater proportion of
the CAS-DN group required CAS for symptomatic carotid
diseases (39.5%; p ¼ 0.012), and plaque morphology was
more complex, with a greater likelihood of longer and ul-
cerated stenoses being found. In addition, these patients did
have signiﬁcantly higher rates of composite in-hospital all-
cause death, MI, and stroke compared with the CAS-R
group after propensity-score matching. In-hospital new
adverse neurological event rates were signiﬁcantly lower
among the symptomatic population who had previous ipsi-
lateral revascularization, potentially due to a possible lower
relative embolic risk of the restenotic carotid artery versus
de novo atheromatous disease at the time of CAS. Within
the repeat revascularization group, there was a nonsignif-
icant trend toward a lower rate of composite in-hospital all-
cause death, MI, and stroke in patients undergoing repeat
CAS versus CAS after CEA, although this comparison
was underpowered given the low number in the repeat
CAS group.Despite CAS in the repeat revascularization group being
associated with a reduced periprocedural event rate, a 2.2%
risk of in-hospital stroke or TIA remained, although the
actual recorded in-hospital stroke rate was 1.4%. A very
high rate of embolic protection use during CAS was
evident in both the CAS-R and -DN groups. Thirty-day
follow-up data, which were complete in 77.8% of the CAS-
R patients, yielded a stroke rate of 3.2%, which was not
signiﬁcantly lower than that in those undergoing de novo
CAS (4.5%; p ¼ 0.77). We found that a large number of
documented stroke events were determined to have
occurred during the post-hospital discharge to 30-day
event period: 56% and 47% for the CAS-R and -DN
groups, respectively. It is also worth noting that the risk of
stroke, although high in the periprocedural period, persists
after successful CAS. The optimal drug therapy post-CAS
remains unclear. Many operators routinely continue dual
antiplatelet therapy for a number of months. In this study,
discharge medications were not signiﬁcantly different be-
tween groups and included aspirin in >90% and clopi-
dogrel in >92% of patients (data not shown). Likewise,
rates of warfarin prescribed at the time of hospital discharge
were similar (8.2% and 7.7%; p ¼ 0.74, CAS-R vs. CAS-
DN). The etiology of these late embolic events is unclear.
Previous registry data reported 38% of strokes occurring
after 24 h of CAS, with 20% occurring post-discharge from
the hospital (25). Minimizing the risk of CAS-related and
post-procedure cerebrovascular adverse events is vital to the
success of carotid revascularization. Further studies are
necessary to investigate the etiology, timing, and features
associated with stroke in this setting. In addition, studies
may also be needed to ascertain the durability of CAS for
in-stent restenosis or restenosis after CEA.
Study limitations. Several limitations, including those related
to retrospective design, are inherent to our study ﬁndings.
The patient and procedural data analyzed are drawn from a
large, observational, and self-reported voluntary registry
across 141 participating institutions, but may not be appli-
cable to all CAS centers. Although the CARE registry uses
standardized data collection in addition to the implementa-
tion of quality controls, there are likely to be additional pa-
tient characteristics such as socioeconomic and health
variables, among others, that were not recorded and may
differ signiﬁcantly between groups. Furthermore, core labo-
ratory evaluation of both noninvasive and invasive carotid
imaging was not performed as part of the CARE registry
data, thereby potentially leading to additional sources of
confounding and inaccuracy. In the previous revascularization
group undergoing CAS, it was not possible to differentiate
those patients who required repeat revascularization for
progressive carotid artery stenosis from the previous CAS or
CEA site. Thirty-day follow-up results were available for
78% of the patients.
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186Conclusions
Analysis of data from the CARE registry indicates that CAS
for patients with restenosis after previous ipsilateral carotid
revascularization is comparable to CAS for de novo carotid
artery disease. CAS-R patients had lower rates of composite
in-hospital death, stroke, or MI compared with CAS for de
novo disease. This was due primarily to a reduced rate of in-
hospital neurovascular complications. Thirty-day outcomes
were comparable in both CAS groups.
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